Premier Research Unveils IPO Prospectus: Customized CRO Solutions Empower Chinese Pharma Innovation

In recent years, driven by advancements in medical device technology, the booming innovative drug market, the maturation of supporting supply chains, and favorable national policies, China’s pharmaceutical manufacturing industry has maintained strong growth. Numerous small and medium-sized biotechnology firms and various pharmaceutical companies are actively pursuing medical innovation, expanding into global markets, and demonstrating steadily enhancing competitiveness within the international landscape.

As innovation gradually becomes the central theme of the industry, innovative drugs will undoubtedly become a key direction for transformation among many enterprises. Meanwhile, the rapid development of the industry has also introduced numerous uncertainties and challenges. Against this backdrop, the CRO market has experienced robust growth. To address various issues and cope with increasingly stringent new drug approval requirements and the growing complexity of drug R&D, pharmaceutical companies have begun to collaborate with CRO firms to support their research and development efforts. However, compared with the mature CRO markets in Europe and the United States, China’s CRO industry started later, leaving many Chinese pharmaceutical companies confused or facing difficulties when selecting CRO partners.

Premier Research, a global clinical research CRO founded in 1989, has been providing Chinese clients with end-to-end services spanning from the clinical development stage to the commercial launch of new drugs since entering the Chinese market in 2019, accumulating extensive experience in meeting local customer needs. Premier Research’s team of experts has specifically summarized strategies for selecting CROs for domestic biotechnology and small- to medium-sized pharmaceutical companies.

New drug development is not only costly and time-consuming, but also subject to stringent regulations and characterized by low success rates. Currently, China’s healthcare industry widely faces challenges such as insufficient R&D capabilities, relatively inadequate R&D infrastructure and conditions, weak capacity for translating scientific and technological achievements into practical applications, and a lack of understanding of the international regulatory landscape.

In the face of industry changes, pharmaceutical companies can reduce R&D costs, shorten development timelines, improve R&D quality, and mitigate risks by partnering with a suitable Contract Research Organization (CRO) to entrust specialized tasks to professionals. Currently, mainstream CROs in the market primarily offer preclinical CRO and clinical research CRO services, while a select few possess comprehensive outsourcing capabilities.

Generally speaking, the selection of a CRO can be evaluated based on four key criteria:

(1) Expert Team

This includes whether the CRO company has senior experts corresponding to the R&D project, whether its organizational structure and personnel division of labor are clear and reasonable, and whether a dedicated service team has been assigned to the project.

(2) Management System and Equipment

This includes whether there are professional project, quality, and compliance management systems in place, whether the equipment meets project requirements, and whether a professional data management system is available.

(3) Project-related Experience

Does the candidate possess extensive experience in relevant fields to proactively mitigate risks and thereby ensure project timelines?

(4) Familiarity with the Chinese Market

Do we fully understand local customer needs and the variations in regulatory environments to ensure the accuracy and high quality of submission dossiers?

When small and mid-sized biotechnology companies and pharmaceutical enterprises face the decision of selecting a contract research organization (CRO), they often find that large international CROs can provide high-quality services but at a high cost and with limited familiarity with the local market; meanwhile, some emerging domestic CROs may offer reasonable pricing, but frequently suffer from talent shortages and lower levels of professionalism.

Pei Ming, Head of Business Development for Greater China at Premed Pharma, who has been deeply engaged in the pharmaceutical R&D sector for over a decade, analyzed, “In recent years, based on widespread feedback from domestic innovative pharmaceutical clients, there is a sustained high demand for CROs with global coverage and global experience. On the other hand, these clients are no longer satisfied with the standardized processes of large CRO firms and have raised their expectations for customized client experiences. Since product development in different therapeutic areas requires expertise from corresponding specialists, it is unnecessary to blindly pursue the comprehensive capabilities of large global CRO companies. In this context, ‘small but specialized’ global clinical research CROs represent a better choice.”

“Small but Beautiful” Global CRO Premed Pharma has organized specialized teams for its focused therapeutic areas, truly realizing the philosophy of “letting professional teams handle professional tasks.”

Since entering the Chinese market, Pumeier Pharma has been dedicated to facilitating the global expansion of Chinese pharmaceutical companies. Unlike domestic CROs that rely on a “subcontracting” model to conduct overseas clinical trials, Pumeier Pharma maintains professional teams in major countries and regions worldwide, offering a more comprehensive and specialized approach to managing international clinical research projects. Compared with large multinational CROs, Pumeier Pharma places greater emphasis on customer experience, tailoring “small yet elegant” optimal strategies to meet the personalized needs of each client.

As a global clinical research CRO, Premier Research specializes in providing end-to-end services for global regulatory registration and clinical trials in the biopharmaceutical and medical device sectors, with operations spanning the globe. Its CRO services cover virtually all therapeutic areas in biopharmaceuticals, including oncology, dermatology, psychiatry, rare diseases, pediatrics, and cardiovascular diseases, as well as related clinical trial services for medical devices. For more information, please visit Premier Research’s China website (insert CN site) or follow its official WeChat account: Premier Research.